NRX Pharmaceuticals Q3 2026: FDA Ketamine Approval Boosts Revenue & Cuts Losses
NRX Pharmaceuticals Q3 2026: six‑fold revenue jump after FDA approval of preservative‑free ketamine, net loss cut to $2.2 m, cash now $19.8 m, and new DARPA contract fuels future growth.
3 minutes to read

